MENU
APR 20, 2021 4:30 PM PDT

Advancing AAV: Novel Synthesis and Sequencing Solutions for Gene Therapy Research

Sponsored by: GENEWIZ
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Strategic Technical Specialist, GENEWIZ, A Brooks Life Sciences Company
    Biography

      Dr. Andrea O'Hara earned her Ph.D. in genetics and molecular biology from the University of North Carolina at Chapel Hill, and has more than 11 years of experience in next generation sequencing (NGS). She is currently a strategic technical specialist at GENEWIZ within the NGS team.


    Abstract

    Interest in cell and gene therapy-based disease prevention and treatment has increased rapidly over the last few decades, however there are still many hurdles to overcome and further progress to be made in the field. In this presentation, Dr. Andrea O’Hara will discuss GENEWIZ’s innovative gene therapy solutions across the clinical development pipeline, highlighting adeno-associated virus (AAV) plasmid DNA sequencing (RUO/GLP), preparation, and synthesis solutions for recombinant AAV (rAAV) production, which includes confirmation, maintenance, and correction of inverted terminal repeat (ITR) regions. She will also talk about GENEWIZ’s proprietary Sanger & next generation viral genome sequencing confirmation solutions post-AAV packaging. This includes sequencing validation of packaged materials to confirm rAAV vector integrity and identify DNA contaminants in AAV library preparation utilizing short- and long-read whole genome sequencing solutions. Finally, she will discuss novel approaches to stratify and characterize host-immune response and measure rAAV expression during and after treatment.

    Learning Objectives:

    1. The structure of the AAV genome and how it's used in gene therapy research

    2. The challenges associated with AAV usage, and proprietary solutions that can be used to overcome these obstacles

    3. The importance of Illumina® short-read and PacBio® long-read sequencing technology for rAAV quality control 


    Show Resources
    You May Also Like
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources
    Attendees
    • See more